Nuvation Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nuvation Bio sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Nuvation Bio: 7 sponsored US clinical trials, 2 recruiting.
Nuvation Bio sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Platinum-resistant Ovarian Cancer (PROC), with 1 trials.
Upper-quartile sponsor footprint
Nuvation Bio sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05252390
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
NCT04541225
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
NCT02279433
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Nuvation Bio pipeline
2 recruiting of 7 indexed (29% open); 1 completed (14%).
Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Platinum-resistant Ovarian Cancer (PROC) (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nuvation Bio: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Nuvation Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Nuvation Bio page
7 registered trials is a research-attention snapshot, not an endorsement of Nuvation Bio or any single study.
- 2 of Nuvation Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Platinum-resistant Ovarian Cancer (PROC) is the condition Nuvation Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Platinum-resistant Ovarian Cancer (PROC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nuvation Bio pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.